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Abstract
Background: This study was designed to assess the prevalence of smoking at time of lung cancer diagnosis in a
surgical patient cohort referred for cardiothoracic surgery.
Methods: Retrospective study of lung cancer patients (n = 626) referred to three cardiothoracic surgeons at a
tertiary care medical center in Southern California from January 2006 to December 2008. Relationships among
years of smoking cessation, smoking status, and tumor histology were analyzed with Chi-square tests.
Results: Seventy-seven percent (482) had a smoking history while 11.3% (71) were current smokers. The length of
smoking cessation to cancer diagnosis was <1 year for 56 (13.6%), 1-10 years for 110 (26.8%), 11-20 years for 87
(21.2%), 21-30 years for 66 (16.1%), 31-40 years for 44 (10.7%), 41-50 years for 40 (9.7%) and 51-60 years for 8 (1.9%).
The mean cessation was 18.1 ± 15.7 years (n = 411 former smokers). Fifty-nine percent had stage 1 disease and
68.0% had adenocarcinoma. Squamous cell carcinoma was more prevalent in smokers (15.6% vs. 8.3%, p = 0.028);
adenocarcinoma was more prevalent in never-smokers (79.9% versus 64.3%, p = 0.0004). The prevalence of
adenocarcinoma varied inversely with pack year (p < 0.0001) and directly with years of smoking cessation (p =
0.0005).
Conclusions: In a surgical lung cancer cohort, the majority of patients were smoking abstinent greater than one
decade before the diagnosis of lung cancer.
Background
Lung cancer is the leading cause of cancer death,
accounting for 29% of total cancer deaths in the US and
over 1.4 million deaths worldwide. In the US alone, lung
cancer claimed the lives of 171,840 individuals in 2008
and an estimated 159,000 adults will die of lung cancer
in 2009 as compared to a combined mortality of
118,000 adults from colorectal, breast, and prostate can-
cer [1]. Smoking plays an important causative role in
lung cancer, first demonstrated in the British Physicians
Study and validated through multiple epidemiologic stu-
dies thereafter [2-5]. Approximately 85% of lung cancer
can be directly attributed to smoking and second hand
smoke [2,3]. Moreover, the risk of developing lung
cancer rises in a dose response relationship with total
duration of smoking [2-5].
The definitive causative relationship between smoking
and lung cancer has resulted in national efforts to
reduce smoking. In the US, public health efforts have
been successful. Smoking prevalence has decreased from
42.4% in 1965 to 17.9% in 2009 [6-10]. Yet, while there
is an overall reduction, the residual effects of smoking
on lung cancer risk remains most notable in former
smokers and a significant proportion of lung cancer is
now diagnosed in former smokers in the United States
[11,12]. In a recent study of 5628 patients diagnosed
with primary lung cancer, 89% had a smoking history
and 49% were former smokers [13]. Former smokers
disproportionately represent the majority of first time
lung cancer patients.
Despite smoking cessation, lung cancer risk persists, as
shown in the 12-year follow up of the Nurses Lung
Health Study where the hazard ratio for lung cancer was
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kers as compared to non-smokers [14]. For patients who
are diagnosed with early stage lung cancer, surgical
resection of the malignancy may be curative. This study
was designed to evaluate the prevalence of smoking at
the time of lung cancer diagnosis in a surgical cohort of
lung cancer patients. This study’s secondary aim was to
examine relationships between smoking status, preva-
lence and years of smoking cessation, stage and histol-
ogy of lung cancer.
Methods
Retrospective analysis of 660 patients (January 2006-
December 2008) with non-small cell and small cell lung
cancer was performed at Cedar Sinai Medical Center.
Thirty-four patients were excluded based on incomplete
pathology reports. Patients were divided into subgroups
based on stage of lung cancer (I, II, III, IV), and lung
cancer pathology (adenocarcinoma, squamous cell, ade-
nosquamous, small cell, large cell, bronchoalveolar carci-
noma, and undifferentiated carcinoma) based on site of
primary tumor. Smoking status was self-reported by the
patient. Patients described their own smoking status as
either non-smoker or history of smoking. For patients
who had a history of smoking, the choices for describing
smoking history were packs per day, and number of
years smoked. No investigation was performed to verify
the accuracy of the patient’s self-reported smoking his-
tory. Analysis was performed using the data set gener-
ated from intake history questionnaire and pathology
reports. The protocol was approved by the institutional
review board of Cedar Sinai Medical Center (IRB
Pro00019964) and was carried out in accordance with
its ethical and legal requirements.
Statistical Analysis
Numerical variables were summarized as mean ± stan-
dard deviation or median (interquartile range [IQR]).
Categorical variables were summarized as frequencies
and percents. The smoking cessation length variable was
grouped into ordinal levels by 10-year increments: 0-10
years, 11-20 years, 21-30 years, 31-40 years, 41-50 years
and 51-60 years. The pack year (PY) variable was
grouped into ordinal levels by increments: 0, 1-20,
21-50, 51-100, and 100+ pack years. The adenocarci-
noma and non-adenocarcinoma histology variables were
grouped as categorical variables. The squamous cell car-
cinoma and non-squamous cell carcinoma histology
were grouped as categorical variables.
Relationships between categorical variables were
assessed by Chi-Square or Fisher exact tests. The
Cochran-Armitage trend test (1-sided) was used to
assess the relationship between the percent of patients
with Adenocarcinoma and PY and the relationship
between the percent of patients with Adenocarcinoma
and length of smoking cessation. Relationships between
ordinal variables were assessed by Spearman correlation.
The 5% significance level was used throughout. Statisti-
cal calculations were performed using SAS version 9.1
(SAS Institute, Cary, NC). Figures were created using
Microsoft Excel (Microsoft Excel for Mac 2004, Version
11.5.8).
Results
Six-hundred twenty six complete patient records were
identified and included in analysis. Of these 626
patients, 321 (51.3%) were male and 305 (48.7%) were
female. The mean age was 70.1 ± 10.9 years. (Table 1)
Seventy-seven percent had a smoking history but only
11.3% of patients were current smokers. For former
smokers (n = 411), the length of smoking cessation to
cancer diagnosis was <1 year for 56 (13.6%), 1-10 years
for 110 (26.8%), 11-20 years for 87 (21.2%), 21-30 years
for 66 (16.1%), 31-40 years for 44 (10.7%), 41-50 years
for 40 (9.7%) and 51-60 years for 8 (1.9%). (Figure 1) Of
patients with a smoking history, 14.7% were ongoing
smokers. (Table 1) Among patients with a smoking his-
tory, patients had quit smoking an average of 18.1 ±
15.7 years (median 16, IQR 3 to 30) before they were
diagnosed with lung cancer. Of patients with a smoking
history, 117 (18.7%) smoked 1-20 packs per year, 227
(33.0%) had smoked 21-50 pack years, and 131 (20.9%)
had smoked 51-100 pack years. Three hundred sixty-
eight (58.8%) patients were found to have stage 1
disease, 96 (15.4%) had stage 2 disease, 149 (23.8%)
had stage 3 disease and 13 (2.1%) had stage 4 disease.
(Table 1) Adenocarcinoma was the most common
histology, with an overall prevalence of 68%. The non-
adenocarcinoma lung cancer types included 87 (13.9%)
squamous cell carcinoma, 34 (5.4%) adenosquamous cell
carcinoma, 32 (5.1%) bronchoalveolar cell carcinoma,
24 (3.8%) large cell carcinoma, 14 (2.2%) small cell car-
cinoma, and 10 (1.6%) undifferentiated non-small cell
lung cancer.
The histology of lung cancer differed across smoking
s t a t u s .( p=0 . 0 0 7 ,F i g u r e2 )P o s th o ct e s t ss h o w e dt h a t
the percent of lung cancer patients with adenocarci-
noma was lower in smokers than in never-smokers
(64.3% versus 79.9%, p = 0.0004). In contrast, the per-
cent with squamous cell carcinoma was higher in smo-
kers than in never-smokers (15.5% versus 8.3%, p =
0.028). (Figure 2)
Among persistent smokers, the percent of patients
with adenocarcinoma varied inversely with pack years.
As pack years (PY) increased, the percentage of adeno-
carcinoma decreased (p < 0.0001). (Figure 3) The likeli-
hood of having adenocarcinoma varied directly with
years of smoking cessation. (p = 0.0005) (Figure 4)
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Smoking plays an important causative role in the patho-
genesis of lung cancer [2-5]. Lung cancer patients may
face stigmatization for having smoked in the past or
present, and are widely believed to be ongoing smokers
who resist cessation [15]. In this cohort of surgical lung
cancer patients, the prevalence of lung cancer was high
in those patients who quit smoking over one or more
decades before developing lung cancer. In this cohort,
only 11.3% of all patients and 14.7% of patients with a
Table 1 Patient Characteristics (n = 626)
Demographics Number %
Gender
Male 321 51.3
Female 305 48.7
Age (Mean ± SD) 70.1 ± 10.9
Age (Median, Range) 71, 22-97
Age ≤ 70 304 48.6
Age > 70 322 51.4
Pathologic Stage
1 368 58.8
2 96 15.3
3 149 23.8
4 13 2.1
Years of Smoking Cessation for Former Smokers: Mean ± SD 18.1 ± 15.7
Years of Smoking Cessation for Former Smokers: Median, IQR 16, 3-30
Less than 1 year 56 13.6
1-10 years 110 26.8
11-20 years 87 21.2
21-30 years 66 16.1
31-40 years 44 10.7
41-50 years 40 9.7
51-60 years 8 1.9
Smoking Status
Current Smokers 71 11.3
Former Smokers 411 65.7
Never-smokers 144 23.0
Pack Year (PY)
0 144 23.0
1-20 117 18.7
21-50 207 33.1
51-100 131 20.9
≥ 100 27 4.3
Tumor Histology
Adenocarcinoma 425 67.9
Non-adenocarcinoma 201 32.1
Detailed Tumor Histology
Adenocarcinoma (A) 425 67.9
Adenosquamous (ASQ) 34 5.4
Squamous (SQ) 87 13.9
Bronchoalveolar (BAC) 32 5.1
Large Cell (L) 24 3.8
Small Cell (S) 14 2.2
Undifferentiated (U) 10 1.6
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prior studies, we found that, in our cohort, adenocarci-
noma was less prevalent in patients with a heavy smok-
ing history [16,17].
Our study supports that smoking plays an important
causative role in lung cancer pathogenesis, years after
smoking cessation. Studies cite the “quitting ill effect” or
the excessive lung cancer risk experienced by former
smokers 5 years directly following smoking cessation.
Garfinkel and Stellman observed that while smokers
often quit as a result of symptoms or a life threatening
condition, the risk of lung cancer immediately following
cessation is often greater than that for smokers who
continue to smoke [18,19].” Even though these patients
had quit smoking, they may be considered ongoing smo-
kers as they often quit smoking as a direct result of lung
cancer symptoms such as shortness of breath, cough,
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Figure 1 Years of Smoking Cessation to Lung Cancer Diagnosis
versus Percent of Former Smokers, n = 411. Sixty percent of
patients in a surgical lung cancer cohort with a smoking history had
stopped smoking 11-60 years (mean 18.1 ± 15.7, median 16, IQR 3
to 30) before lung cancer diagnosis.
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Figure 2 Lung Cancer Histology by Smoking Status. Lung Cancer histology differs by smoking status (p = 0.007). The percent of lung cancer
patients with adenocarcinoma was lower in current and former smokers than in never-smokers (64.3% versus 79.9%, p = 0.0004), while the
percent with squamous cell carcinoma was higher in smokers than in never-smokers (15.5% versus 8.3%, p = 0.028).
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term smoking history itself, whether the patient is a
persistent smoker or not, predisposes the patient to
increased cancer risk.
While the surgical cohort of lung cancer patients had
generally stopped smoking decades before, tobacco’s
carcinogenic effects persisted. (Figure 1) Case control
and cohort studies show a 50% decrease in the risk of
lung cancer within first 15 years of abstinence, but the
risk never drops to that of non-smokers [20]. A pro-
spective cohort study of 41,836 women aged 55 to
69 years showed that the relative risk remained 6.6 for
all former smokers 30 years after smoking abstinence
[21]. Furthermore, studies suggest that excess lung can-
cer risk persists beyond 10 to 15 years of smoking absti-
nence [22]. Sixty percent of our cohort developed lung
cancer despite stopping smoking over one decade ago.
The major limitation of our study is the selection bias
for lung cancer patients who were referred to cardi-
othoracic surgeons in a tertiary care medical center.
Our surgical lung cancer cohort may represent an atypi-
cal lung cancer cohort group. The vast majority of our
study patients had early stage disease and was asympto-
matic at the time of diagnosis. In our cohort, 58.8% of
patients were diagnosed stage 1, 15.3% were diagnosed
with stage 2 disease, while 25.9% patients presented
with stage 3 and 4 disease. In contrast, in the general
population, more than half of lung cancer patients are
diagnosed at an advanced stage, and they are more likely
to experience shortness of breath, cough, and hemopty-
sis and/or weight loss and fatigue. From 1999-2006, the
National Cancer Institute showed that only 16% of lung
cancer was diagnosed at the early stage, while 25% were
diagnosed after they had spread regionally beyond the
primary site to lymph nodes and 51% were diagnosed
with distant metastases [23].
Surgically referred lung cancer patients may be more
likely to be former smokers as compared to patients
who are diagnosed with advanced stage disease. We
noted that, in the patient cohort referred for cardiothor-
acic surgery, only 11.3% current smokers. In contrast, a
sectional study of all lung cancer patients from 1986 to
1990 at M.D. Anderson Cancer Center found that 47.8%
of lung cancer patients were current smokers[24]. The
MD Anderson study represented all lung cancer patients
referred for medical and surgical management of lung
cancer. Our findings may not generalizable to the over-
all lung cancer population.
Extrapolating patterns from our cohort to the general
population is also limited by our study’s reliance on ret-
rospective data collection and the referral center’s loca-
tion in Southern California. First, data collection was
dependent on patient reporting smoking history. Given
the stigmatization of smoking in the medical community,
patients may be more likely to underestimate their pack
year smoking history [25]. Furthermore, patient selection
bias may also derive from the study center’s location in
Southern California. This medical center will typically see
residents of Southern or Northern California. California
was one of the first states to ban on smoking in all
enclosed workspaces (1995), and subsequently enacted
strict anti-smoking laws in the majority of public spaces
[26]. Thus, patients in California may have had dispro-
portionately higher rates of smoking cessation following
anti-smoking laws implementation as compared to other
states [27]. In the first decade after a comprehensive
tobacco control program was implemented in California
(1988), there was a 6% reduction in lung cancer incidence
and 11,000 lung cancer cases were avoided [28]. Our
patient cohort may be more likely than patients in other
states to be former smokers as a result of environmental
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Figure 3 Pack Years (PY) versus Lung Cancer Tumor Histology,
n = 626. The percent of lung cancer patients with adenocarcinoma
decreases with increasing Pack Years (PY), p < 0.0001.
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places are associated with reductions in prevalence of
smoking of 3.8% and 3.1 fewer cigarettes smoked per day
per continuing smoker [29].
Conclusions
In conclusion, there is a low prevalence of ongoing smok-
ing in our lung cancer surgical cohort; and the majority
of these patients were smoking abstinent at least one or
more decades. The median length of smoking cessation
was 16 (3 to 30) years, and the mean length of smoking
cessation was18.1 ± 15.7 years (Figure 1) As more states
adopt stringent tobacco control programs like California,
we may expect a proportional increase in the prevalence
of smoking cessation, a lengthened period of smoking
cessation and an increase in the proportion of early stage
lung cancers at time of diagnosis. This prediction is
supported by data gathered following enactment of
California’s Tobacco Control programs. Following the
passage of the 1988 California Comprehensive Tobacco
Control Program, California experienced a 18% decrease
in lung cancer incidence from 1990-94 to 1995-99 [30].
From 1988-99, lung cancer rates declined 19.5% accord-
ing to the California Department of Health Services. In
contrast, states with lenient tobacco programs noted a
rise in lung cancer rates while states with stringent
tobacco control programs experienced an accelerated
decline in lung cancer rates [31]. Specifically, the
California Tobacco Control program was associated with
a significantly greater rate of decline in the age-adjusted
incidence rate for lung cancer as compared to eight other
s i t e sa c r o s st h en a t i o n .
32 Support for this trend was
shown as California’s 1999 rate of lung cancer was 10.4%
lower than the national incidence rate of lung cancer
[32]. Our study may give us a glimpse into the future of
lung cancer and its changing demographic trends in
California and the US.
Despite strides in smoking prevention and environ-
mental pressures to discourage smoking, it is clear that
lung cancer will continue to be a major threat to public
health. While rates of death from breast and prostate
have leveled off, death from lung and bronchus cancer
has only begun to plateau from their rapidly rising mor-
tality rate. Understanding the patterns of smoking his-
tory, tumor stage/histology, and years of smoking
cessation in our surgical lung cancer cohort may allow
the clinician to better counsel our patients to optimize
their cancer management and promote cancer preven-
tion. A substantial risk of developing lung cancer per-
sists in former smokers many years following smoking
cessation. If screening for lung cancer is recommended
in the future, it should be continued for decades after
smoking cessation.
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